|
|
| 2005 |
| Completed $12.5 million convertible note offering. |
| Elected John T. Spitznagel as Chairman of the Board of Directors
|
| 2004 |
| Commenced limited IRX-2 Phase I trial |
| 2003 |
Received FDA grant of IRX-2 Fast Track Designation
Received FDA approval of IRX-2 IND Application |
| Filed Fast Track Designation application for IRX-2 |
| Filed IND Application for IRX-2 |
| 2002 |
| Recruited Medical Advisory Board with Ashok Shaha, MD of Memorial Sloan-Kettering as Chairman |
| Elected John T. Spitznagel, CEO of ESP Pharma, to Board of Directors |
Validated multiple IRX-2 quality control and manufacturing consistency assays
Manufactured first cGMP lot of IRX-2 |
| Retained Jeffrey Hwang as Chief Financial Officer |
| 2001 |
Elected new Directors: Howard Stevenson, a senior Harvard Business School entrepreneurship professor and accomplished business builder; and, Ferid Murad, MD, PhD, 1998 co-recipient of the Nobel Prize in Medicine and former head of R&D for Abbott Laboratories
Retained Zygmund Roth, PhD, as Vice President, Regulatory Affairs & Quality Assurance Completed pre-IND meeting with the FDA for IRX-2 Filed three patent applications to enhance intellectual property portfolio |
|
© 2011 IRX Therapeutics
|
|
